99 related articles for article (PubMed ID: 19106660)
1. Molecule-targeted agents in endometrial cancer.
Delmonte A; Sessa C
Curr Opin Oncol; 2008 Sep; 20(5):554-9. PubMed ID: 19106660
[TBL] [Abstract][Full Text] [Related]
2. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.
Gadducci A; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2006 Jun; 58(3):242-56. PubMed ID: 16436330
[TBL] [Abstract][Full Text] [Related]
3. Molecular targets and targeted therapeutics in endometrial cancer.
Weigelt B; Banerjee S
Curr Opin Oncol; 2012 Sep; 24(5):554-63. PubMed ID: 22581357
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapy in metastatic or recurrent endometrial cancer.
Pectasides D; Pectasides E; Economopoulos T
Cancer Treat Rev; 2007 Apr; 33(2):177-90. PubMed ID: 17196749
[TBL] [Abstract][Full Text] [Related]
5. Molecular target therapies in endometrial cancer: from the basic research to the clinic.
Gadducci A; Tana R; Cosio S; Fanucchi A; Genazzani AR
Gynecol Endocrinol; 2008 May; 24(5):239-49. PubMed ID: 18569027
[TBL] [Abstract][Full Text] [Related]
6. Management of advanced-stage and recurrent endometrial cancer.
Ray M; Fleming G
Semin Oncol; 2009 Apr; 36(2):145-54. PubMed ID: 19332249
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells.
Bae-Jump VL; Zhou C; Boggess JF; Gehrig PA
Cancer; 2009 Sep; 115(17):3887-96. PubMed ID: 19484784
[TBL] [Abstract][Full Text] [Related]
8. Target-based therapies in breast cancer: current status and future perspectives.
Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
[TBL] [Abstract][Full Text] [Related]
9. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.
Wagner AD; Moehler M
Curr Opin Oncol; 2009 Jul; 21(4):381-5. PubMed ID: 19412098
[TBL] [Abstract][Full Text] [Related]
10. Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis.
Castellvi J; Garcia A; Ruiz-Marcellan C; Hernández-Losa J; Peg V; Salcedo M; Gil-Moreno A; Ramon y Cajal S
Hum Pathol; 2009 Oct; 40(10):1418-26. PubMed ID: 19428047
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in endometrial cancer treatment.
Morotti M; Valenzano Menada M; Venturini PL; Ferrero S
Expert Opin Biol Ther; 2012 May; 12(5):649-58. PubMed ID: 22428875
[TBL] [Abstract][Full Text] [Related]
12. Resistance to chemotherapy and hormone therapy in endometrial cancer.
Chaudhry P; Asselin E
Endocr Relat Cancer; 2009 Jun; 16(2):363-80. PubMed ID: 19190080
[TBL] [Abstract][Full Text] [Related]
13. Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives.
Capurso G; Fazio N; Festa S; Panzuto F; De Braud F; Delle Fave G
Crit Rev Oncol Hematol; 2009 Nov; 72(2):110-24. PubMed ID: 19249226
[TBL] [Abstract][Full Text] [Related]
14. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
Bertoni E; Salvadori M
J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
[TBL] [Abstract][Full Text] [Related]
15. Systemic therapy for recurrent endometrial cancer: a review of North American trials.
Dellinger TH; Monk BJ
Expert Rev Anticancer Ther; 2009 Jul; 9(7):905-16. PubMed ID: 19589030
[TBL] [Abstract][Full Text] [Related]
16. New targets for therapy of sarcoma.
Magenau JM; Schuetze SM
Curr Opin Oncol; 2008 Jul; 20(4):400-6. PubMed ID: 18525335
[TBL] [Abstract][Full Text] [Related]
17. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?
Petrelli F; Cabiddu M; Ghilardi M; Barni S
Expert Opin Investig Drugs; 2009 Oct; 18(10):1467-77. PubMed ID: 19737114
[TBL] [Abstract][Full Text] [Related]
18. Enhancing the efficacy of hormonal agents with selected targeted agents.
Johnston SR
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
[TBL] [Abstract][Full Text] [Related]
19. Molecular targeted therapies for solid tumors: management of side effects.
Grünwald V; Soltau J; Ivanyi P; Rentschler J; Reuter C; Drevs J
Onkologie; 2009 Mar; 32(3):129-38. PubMed ID: 19295254
[TBL] [Abstract][Full Text] [Related]
20. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A; Perez EA
Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]